• Slide1

Profiling your product through the complex multidimensional relationships between
exposure, biological response, and human health outcome

How Does It Work

How Does It Work

For A Safer Future

For A Safer Future

Contact us

Contact us

  • Banner1

Breaking news

  • ToxGenSolutions BV prepares for tackling a growing health problem: dementia

    #ToxGenSolutions BV is looking for funding of a cross-borders private (SMEs)/public project aiming at expanding our understanding of the early events of neurodegenerative diseases, e.g. #Alzheimers. One deliverable is a novel tool for early diagnosis of neurodegenerative diseases, e.g. Alzheimers. The project will focus on the #animalfree identification of the molecular and cellular mechanisms triggered by a selection of relevant environmental chemicals and pharmaceuticals in human induced pluripotent stem cells (#iPSC), and iPSC-derived human brain tissue, with and without genetic mutations observed in Alzheimers patients. Early diagnosis is the first step towards improved therapies capable of suppressing disease progression. It is also anticipated that this project allows for the identification of new targets for drug development, having an additional positive impact on the quality of therapy.
  • Saxocon ApS (DK) and ToxGenSolutions BV (NL) join forces to improve #animalfree product development

    (Q)SAR modeling is currently used to identify chemicals having desired physico-chemical/structural characteristics (e.g. new leads for drug development), or exhibiting characteristics known to exert adverse effects in humans (e.g. hazard identification and safety testing). It is not well established yet how well these (Q)SAR models discriminate chemicals with similar physico-chemical/structural characteristics but different in vivo outcome. This is a problem e.g. when in vivo animal models incorrectly indicate unsatisfactory efficacy or toxicity. By combining physico-chemical/structural analysis [Saxocon ApS (DK)] and biological pathway analysis of exposed human cells and tissue [ToxGenSolutions BV (NL)], both companies are convinced that they can offer costumers a novel quantitative #animalfree systems biology approach for efficacy/toxicity assessment, and more accurate human health and safety, where current in vivo animal models fail.
  • Application nr. 14/028.308 'In vitro method for determining immunotoxicity of a compound' is now also allowed for issuance as a patent in the USA

    Main claim: An in vitro method of detecting altered expression of at least one marker gene in response to a compound, the method comprising: - exposing a nucleated cell to the compound; - detecting the level of the at least one marker gene expressed by the nucleated cell after exposure to the compound; and - detecting altered expression of the at least one marker gene if the level of expression of the at least one marker gene is above or below a predetermined reference value for the level of expression of the at least one marker gene; - wherein the at least one marker gene is selected from the group consisting of ABCA1, CHAC1, CRIM1 and HMGCS1; and - wherein the immunotoxicity of the compound is not known.
  • EPO has granted a European patent on the basis of the application 12 184 575.4-1402 ''In vitro method for determining immunotoxicity of a compound''

    Claim 1: In vitro method for determining whether a compound is immunotoxic wherein the expression level of at least one marker gene is determined in a sample obtained from a Jurkat cell culture in vitro, which is exposed to the compound in the in vitro culture, wherein the marker gene is ABCA1, and wherein it is concluded that the compound is immunotoxic if the expression level of the ABCA1 marker gene is below or above a predetermined reference value. Claim 2: Method according to claim 1 wherein the expression level of three additional marker genes is determined in the sample obtained from the Jurkat cell cultured in vitro wherein it is concluded that the compound is immunotoxic if the expression level of at least one additional marker gene is below or above a predetermined reference value wherein the additional marker genes are CHAC1, CRIM1 and HMGCS1.
  • Banner03

How does it work

A VIRTUAL GENERIC GENOMICS-BASED PLATFORM THAT PROVIDES ANSWERS TO YOUR QUESTIONS ABOUT SAFETY AND EFFICACY OF YOUR PRODUCTS.

 

Next-generation tools

  • A systems-based technology platform for profiling the positive as well as negative impact of your product on biological response and human health at realistic concentrations and under relevant exposure regimes.
  • Our toolbox contains a breadth of technologies, systems, and pathways of toxicity and common nodes of toxicity developed by the Netherlands ToxicoGenomics Center (2008-2013).
  • The ToxGenSolutions toolbox is also useful for the identification of new opportunities for product development
  • The ToxGenSolutions toolbox is flexible, faster than traditional methods, more economical and more relevant for human safety and health.

Front-edge technologies

  • ToxGenSolutions products are proprietary mechanism-based gene signatures for identification and classification of toxicants during screening, product development and safety assessment.
  • ToxGenSolutions provides a cutting-edge patchwork of test methods required for modern testing and assessment of compounds and products.
  • ToxGenSolutions builds on a virtual generic platform of leading test and technology developers providing novel technologies addressing key events in outcome pathways.

Focus on your needs

  • ToxGenSolutions develops testing and assessment strategies for, and with, you to assure optimal coverage of your needs.
  • ToxGenSolutions develops strategies considering the nature of the test substance, the intended application, likely exposure routes, product development status and legislation.
  • Banner4

For a safer future

THE WORKING HYPOTHESIS IS THAT THE COMBINATION OF EXPERTISE AND TECHNOLOGY FROM DIFFERENT DISCIPLINES WILL PROVIDE THE UNDERSTANDING OF HOW CHEMICALS INTERACT WITH BIOLOGICAL SYSTEMS THAT IS REQUIRED TO IMPROVE HUMAN SAFETY AND HEALTH.

Animal-free chemical safety assessment
Aligning the 3Rs with new paradigms in the safety assessment of chemicals
Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment
  • Banner4

Still on the table

A novel therapy for slowing down the progression of neurodegenerative diseases through a better understanding of the impact of environmental chemicals on neurodegeneration induction.

The incidence of neurodegenerative diseases (e.g. Alzheimer’s, Parkinson, multiple and amyotrophic lateral sclerose) is globally on the rise, and the increasing number of patients is challenging the existing medical care ressources. While these diseases are driven by genetics, there is also an important environmental input. Despite decennia of intensive research early diagnose and effective therapy of these diseases is not yet possible. There are two important hurtles: 1. The underlying mechanisms of induction of neurodegeneration in humans are still not sufficiently understood; 2. The blood-brain barrier allows only chemicals with specific physicochemical charactereistics to enter the brain. ToxGenSolutions BV envisages a project addressing the mechanistic aspects (Hurtle 1). -Omics approaches based on human stemcells and tissues are anticipated (i) to provide better and more relevant knowldege about the mechanisms affected by environmental factors and driving the induction of neurodegenerative diseases in humans, and (ii) to allow for the identification of human-relevant early biomarkers. Thus, the acquired knowledge offers new opportunities for the development of novel more accurate methods for early diagnosis of disease induction. In addition, alternative targets for novel anti-neurodegenerative drugs are anticipated to emerge from this project.

Improving #animalfree testing and assessment by combining physico-chemical/structural analysis and biological pathway analysis of exposed human cells and tissuel.

(Q)SAR modeling is currently used to identify chemicals that are most likely to become a product,by having desired physico-chemical/structural characteristics (e.g. new leads for drug development), and by not exhibiting characteristics known to exert adverse effects in humans (e.g. hazard identification and safety testing). It is currently not well established how well current (Q)SAR models discriminate chemicals with similar physico-chemical/structural characteristics but different in vivo outcome. This is a problem e.g. when in vivo animal models incorrectly indicate unsatisfactory efficacy or toxicity. ToxGenSolutions BV envisages a novel quantitative systems biology approach for toxicity assessment linking physico-chemical characteristics of test compounds ((Q)SAR) with biological impact on cells/tissues, providing more accurate human health and safety where in vivo animal models fail.